Literature DB >> 23731764

Characterization of peripheral blood stem cell grafts mobilized by granulocyte colony-stimulating factor and plerixafor compared with granulocyte colony-stimulating factor alone.

Beatrice Gaugler1, Jessy Arbez, Steven Legouill, Pierre Tiberghien, Philippe Moreau, Sophie Derenne, Philippe Saas, Mohamad Mohty.   

Abstract

BACKGROUND AIMS: This study aimed to characterize the immune effectors contained in apheresis samples obtained from patients with grafts mobilized with plerixafor and granulocyte colony-stimulating factor (G-CSF) (P+G) compared with grafts mobilized with G-CSF alone (G).
METHODS: Aliquots of apheresis samples were obtained from 36 patients with malignant diseases after mobilization with G (n = 18) or P+G (n = 18). The phenotype and cytokine secretion profile of T cell and dendritic cell subsets were characterized by multicolor cytometry including intracellular cytokine staining.
RESULTS: In grafts collected after mobilization with P+G, there was a significantly higher percentage of CD3(+) T cells compared with samples collected after mobilization with G alone. On a functional level, a significant increase of interferon-γ and tumor necrosis factor-α secreting CD8(+) T cells was observed in the P+G group compared with the G group. CD4(+)Foxp3(+) regulatory T cells were similar in both groups but exhibited a lower expression of inducible costimulatory molecule and a significantly higher expression of CD127 in the P+G group. Myeloid dendritic cells (MDCs) and BDCA3(+) dendritic cells were similar in both groups. In contrast, plasmacytoid dendritic cells (PDCs) (CD123(+)BDCA2(+)HLA-DR(+)) were significantly increased in the P+G grafts, leading to a higher PDC-to-MDC ratio. PDCs mobilized by P+G displayed different functional markers--a higher percentage of ILT7(+) PDCs and decreased expression of CD86--suggesting a potential regulatory capacity of PDCs mobilized by P+G.
CONCLUSIONS: Grafts mobilized with P+G exhibited major different functional features compared with grafts mobilized with G alone, suggesting that such grafts may have an impact on patient outcome after autologous stem cell transplantation.
Copyright © 2013 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23731764     DOI: 10.1016/j.jcyt.2013.03.013

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  9 in total

1.  The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma.

Authors:  Antonio Curti; Roberto M Lemoli; Giulia Tolomelli; Katia Mancuso; Paola Tacchetti; Francesca Patriarca; Monica Galli; Lucia Pantani; Beatrice Zannetti; Maria Rosa Motta; Simonetta Rizzi; Elisa Dan; Barbara Sinigaglia; Valeria Giudice; Andrea Olmo; Mario Arpinati; Gabriella Chirumbolo; Renato Fanin; Russell E Lewis; Laura Paris; Francesca Bonifazi; Michele Cavo
Journal:  Bone Marrow Transplant       Date:  2019-11-25       Impact factor: 5.483

Review 2.  Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective.

Authors:  F Saraceni; N Shem-Tov; A Olivieri; A Nagler
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

Review 3.  Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers.

Authors:  Y-J Chang; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2014-02-24       Impact factor: 5.483

4.  Collection and Processing of Mobilized Mouse Peripheral Blood at Lowered Oxygen Tension Yields Enhanced Numbers of Hematopoietic Stem Cells.

Authors:  Arafat Aljoufi; Scott Cooper; Hal E Broxmeyer
Journal:  Stem Cell Rev Rep       Date:  2020-10       Impact factor: 5.739

5.  Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial.

Authors:  K E Herbert; L Demosthenous; G Wiesner; E Link; D A Westerman; N Came; D S Ritchie; S Harrison; J F Seymour; H M Prince
Journal:  Bone Marrow Transplant       Date:  2014-06-02       Impact factor: 5.483

Review 6.  Autologous Graft-versus-Tumor Effect: Reality or Fiction?

Authors:  Luis F Porrata
Journal:  Adv Hematol       Date:  2016-08-22

Review 7.  New insights in the mobilization of hematopoietic stem cells in lymphoma and multiple myeloma patients.

Authors:  Maria K Angelopoulou; Pantelis Tsirkinidis; Georgios Boutsikas; Theodoros P Vassilakopoulos; Panayiotis Tsirigotis
Journal:  Biomed Res Int       Date:  2014-08-14       Impact factor: 3.411

8.  Mobilization of healthy donors with plerixafor affects the cellular composition of T-cell receptor (TCR)-αβ/CD19-depleted haploidentical stem cell grafts.

Authors:  Sergio Rutella; Perla Filippini; Valentina Bertaina; Giuseppina Li Pira; Lidia Altomare; Stefano Ceccarelli; Letizia P Brescia; Barbarella Lucarelli; Elia Girolami; Gianpiero Conflitti; Maria Giuseppina Cefalo; Alice Bertaina; Tiziana Corsetti; Lorenzo Moretta; Franco Locatelli
Journal:  J Transl Med       Date:  2014-09-02       Impact factor: 5.531

9.  Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers.

Authors:  Alissa Visram; Christopher Bredeson; David Allan; Mitchell Sabloff; Lothar Huebsch; Jason Tay; Natasha Kekre; Sheryl McDiarmid; Ranjeeta Mallick; Alan Tinmouth; Lisa Martin; Linda Hamelin; Dawn Maze
Journal:  Blood Cancer J       Date:  2018-01-29       Impact factor: 11.037

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.